SVRA

SVRA

USD

Savara Inc. Common Stock

$4.130-0.110 (-2.594%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$4.240

高値

$4.300

安値

$4.115

出来高

0.81M

企業ファンダメンタルズ

時価総額

831.4M

業種

バイオテクノロジー

United States

取引統計

平均出来高

1.53M

取引所

NMS

通貨

USD

52週レンジ

安値 $1.89現在値 $4.130高値 $4.505

関連ニュース

PR Newswire

Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz announces that investors with losses related to Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA) have...

もっと見る
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GlobeNewswire

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Savara To Contact Him Directly To Discuss Their Options If you suffered losses

もっと見る
SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
PR Newswire

Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA

The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the...

もっと見る
Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA
PR Newswire

SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May...

もっと見る
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
BusinessWire

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of

もっと見る
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
PR Newswire

Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRA

Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS...

GlobeNewswire

Savara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SVRA

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ:SVRA). Shareholders who purchased shares of SVRA during the class period listed are

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。